In this interview, filmed at ASH 2018, Dr Constantine Mitsiades talks to touchONCOLOGY about the current and future treatment landscape of multiple myeloma. One of the most significant recent developments in the treatment of multiple myeloma, has been monoclonal antibodies (mAbs), particularly daratumumab. This anti-CD31 mAb has been approved, alone and in combination with other agents, by the US Food and Drug Administration and there are ongoing studies into other combinations. Dr Mitsiades discusses the issues around treating patients who become refractory to daratumumab and how there is still much to learn regarding optimal drug combinations and delivery methods. Looking to the future, Dr Mitsiades describes CRISPR-based functional genomic technologies and how they can be used to learn more about the genes involved in multiple myeloma. He is also interested in how next generation sequencing can be used to derive important information from the non-malignant cells of the tumour micro-environment.
1. What have been the most significant recent developments in the treatment of multiple myeloma? (0:10)
2. What are the current unmet needs and the challenges you face when treating patients? (2:16)
3. What developments are you most excited about in your area over the next few years? (4:07)
4. Which presentations/data have interested you the most at ASH 2018? (5:45)
Speaker disclosures: Constantine Mitsiades has nothing to disclose in relation to this interview.
Filmed at the 60th American Society of Hematology (ASH) 2018 Annual Meeting, San Diego, CA, US, 1–4 December 2018.
Share this Video
Related Videos In Multiple Myeloma
Shaji Kumar, ASCO 2021: The EQUATE Trial, a Quadruplet Regimen for Multiple Myeloma
We were delighted to talk with Dr Shaji Kumar (Mayo Clinic, Rochester, MN, USA) about the EQUATE trial, developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab. The abstract ‘ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended […]
Shaji Kumar, ASH 2020 – Highlights from ASH 2020
It was a pleasure to speak with our Editor-in-Chief, Shaji Kumar (Mayo Clinic, Rochester, MN, USA) to discuss the use of MEDI2228 (Clinical Trial Identifier: NCT03489525) and anti-BCMA CAR-T cells (Clinical Trial Identifier: NCT03915184) in the treatment of patients with relapsed/refractory multiple myeloma and to find out his personal highlights from this year’s congress. The […]
Meletios-Athanasios Dimopoulos, ASH 2020 – Results from the Apollo Trial
We caught up with Meletios-Athanasios Dimopoulos (National and Kapodistrian University of Athens School of Medicine, Athens, Greece) to discuss his ASH 2020 presentation on the use of daratumumab in the treatment of relapsed/refractory multiple myeloma (Clinical Trial Identification: NCT03180736). The abstract ‘412 Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!